Kintor Pharmaceutical Limited (KNTPF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 411.12 Million CNY | -26.58% |
| 2022 | 559.94 Million CNY | 35.64% |
| 2021 | 412.83 Million CNY | 20.17% |
| 2020 | 343.54 Million CNY | 87.0% |
| 2019 | 183.71 Million CNY | 6.86% |
| 2018 | 171.92 Million CNY | 277.8% |
| 2017 | 45.5 Million CNY | 45226.62% |
| 2016 | 100.39 Thousand CNY | -74.18% |
| 2015 | 388.8 Thousand CNY | -2.07% |
| 2014 | 397.01 Thousand CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 347.96 Million CNY | -15.36% |
| 2024 Q2 | 347.96 Million CNY | 0.0% |
| 2023 Q2 | 548.63 Million CNY | 0.0% |
| 2023 FY | 411.12 Million CNY | -26.58% |
| 2023 Q1 | 548.63 Million CNY | -2.02% |
| 2023 Q4 | 411.12 Million CNY | 0.0% |
| 2023 Q3 | 411.12 Million CNY | -25.06% |
| 2022 Q2 | 562.82 Million CNY | 0.0% |
| 2022 Q4 | 559.94 Million CNY | 0.0% |
| 2022 Q1 | 562.82 Million CNY | 36.33% |
| 2022 FY | 559.94 Million CNY | 35.64% |
| 2022 Q3 | 559.94 Million CNY | -0.51% |
| 2021 Q1 | 240.86 Million CNY | -29.89% |
| 2021 FY | 412.83 Million CNY | 20.17% |
| 2021 Q4 | 412.83 Million CNY | 0.0% |
| 2021 Q3 | 412.83 Million CNY | 71.39% |
| 2021 Q2 | 240.86 Million CNY | 0.0% |
| 2020 Q3 | 343.54 Million CNY | -8.71% |
| 2020 FY | 343.54 Million CNY | 87.0% |
| 2020 Q1 | 376.32 Million CNY | 104.85% |
| 2020 Q2 | 376.32 Million CNY | 0.0% |
| 2020 Q4 | 343.54 Million CNY | 0.0% |
| 2019 Q4 | 183.71 Million CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 183.71 Million CNY | 6.86% |
| 2019 Q3 | 183.71 Million CNY | 0.0% |
| 2018 FY | 171.92 Million CNY | 277.8% |
| 2017 Q3 | 45.5 Million CNY | 159.28% |
| 2017 FY | 45.5 Million CNY | 45226.62% |
| 2017 Q1 | 17.55 Million CNY | 17382.04% |
| 2017 Q2 | 17.55 Million CNY | 0.0% |
| 2017 Q4 | 45.5 Million CNY | 0.0% |
| 2016 Q4 | 100.39 Thousand CNY | 0.0% |
| 2016 FY | 100.39 Thousand CNY | -74.18% |
| 2016 Q1 | 980.54 Thousand CNY | 0.0% |
| 2016 Q3 | 100.39 Thousand CNY | 0.0% |
| 2015 FY | 388.8 Thousand CNY | -2.07% |
| 2014 FY | 397.01 Thousand CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -12551.793% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -671.26% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -97421.634% |
| SQZ Biotechnologies Company | 50.03 Million USD | -721.599% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3323.499% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -467.289% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -596.648% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -10574.493% |
| Marizyme, Inc. | 26.67 Million USD | -1441.177% |
| Genus plc | 485 Million USD | 15.233% |
| Pharming Group N.V. | 244.07 Million USD | -68.441% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -20352.409% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -16238.093% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -10718.947% |
| ContraFect Corporation | 32.53 Million USD | -1163.779% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -10640.8% |
| IMV Inc. | 37.93 Million USD | -983.812% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -3390.518% |
| ONE Bio Corp. | 27.49 Million USD | -1395.21% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -431.046% |
| Mesoblast Limited | 188.44 Million USD | -118.165% |
| MultiCell Technologies, Inc. | 1617.67 USD | -25414230.488% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -395.714% |
| Genscript Biotech Corporation | 1.32 Billion USD | 68.992% |
| Neon Bloom, Inc. | 1.22 Million USD | -33427.617% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -7889.063% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -4190.535% |
| Biomind Labs Inc. | 1.49 Million USD | -27333.385% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -4446.684% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -2133.933% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2821.499% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -28572.235% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -6936.568% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -289227.563% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -20649.929% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -4243.159% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -204319.34% |
| Accustem Sciences Inc. | 1.07 Million USD | -37993.508% |
| EV Biologics, Inc. | 2.11 Million USD | -19337.664% |
| Q BioMed Inc. | 8.13 Million USD | -4954.999% |
| GB Sciences, Inc. | 5.41 Million USD | -7488.66% |
| Alpha Cognition Inc. | 7.16 Million USD | -5638.074% |
| CSL Limited | 18.62 Billion USD | 97.792% |
| Agentix Corp. | 2.51 Million USD | -16275.662% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -246.287% |
| Enzolytics Inc. | 365.26 Million USD | -12.553% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | -510.007% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -48916.849% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -7055.113% |
| argenx SE | 444.95 Million USD | 7.603% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -448.745% |
| HST Global, Inc. | 593.59 Thousand USD | -69159.577% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -23885.998% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -32549.483% |
| Halberd Corporation | 728.71 Thousand USD | -56316.808% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1561.358% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -11116.961% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1491140.161% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -3353.89% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -10909.275% |
| AVAX Technologies, Inc. | 3.99 Million USD | -10194.097% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -60284.763% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -15061.299% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -172166.126% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -5130.047% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -614162.876% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -717.921% |
| Kadimastem Ltd | 3.5 Million USD | -11629.974% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2484.902% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -88370.171% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1498533.033% |
| LadRx Corporation | 2.2 Million USD | -18582.789% |
| Cell Source, Inc. | 15.8 Million USD | -2500.92% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -919713.854% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7432.959% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7432.959% |
| Affymax, Inc. | 8.87 Million USD | -4534.427% |
| Mobile Lads Corp. | 1.31 Million USD | -31199.653% |
| Itoco Inc. | 1.65 Million USD | -24768.872% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -19939.336% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -6696.495% |
| International Stem Cell Corporation | 5.27 Million USD | -7690.79% |
| CytoDyn Inc. | 127.89 Million USD | -221.454% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -983464.2% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -26146.555% |
| Qrons Inc. | 1.48 Million USD | -27515.8% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3622.13% |
| SYBLEU INC | 681.41 Thousand USD | -60233.454% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -50731.238% |
| Rebus Holdings, Inc. | 5.24 Million USD | -7742.808% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -6637.568% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -65594.165% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -8804.242% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -902.83% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1746.486% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -20198.343% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -7404.929% |
| Neutra Corp. | 973.52 Thousand USD | -42129.867% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1316.922% |
| PureTech Health plc | 125.58 Million USD | -227.369% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -10842.409% |
| IXICO plc | 1.9 Million USD | -21534.57% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1902.63% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -297.894% |
| CSL Limited | 18.62 Billion USD | 97.792% |
| Cellectis S.A. | 249.36 Million USD | -64.864% |